Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no ...

Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Attorney Robert L. Taylor asked for a judge to try his 2022 sexual assault case. However, on the day the trial was to begin, ...

Workers' compensation rates are affected by several factors. Learn what workers' compensation covers, and how to calculate ...

Ocugen OCGN is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms of action. With all three key pipeline programs moving on schedule, Ocugen ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Yakuza Kiwami 3 and Dark Ties brings a host of gameplay tweaks and new additions to address the criticisms of the original ...

Prefoldin 5 stabilises neuronal microtubules and suppresses Tau-mediated neurotoxicity, offering a potential therapeutic target for tauopathies.

PostsSmall List: the raging rhino slot jackpotRTP Costs & Max Earnings to have Online casino games Real time & Mobile Online ...